BG-T0050 / BeOne Medicines - LARVOL DELTA

A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: BeOne Medicines

First-in-human • New P1 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2